MAY 18, 2019 4:44 PM PDT

How a Cancer Drug Inhibits DNA Repair in Cancer Cells

WRITTEN BY: Nouran Amin

In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow in cancer that uses a specific pathway to create DNA repair cells.

Learn more about DNA repair and damage:

That drug is called Cediranib and when combined with another cancer agent known as olaparib (registered as Lynparza) can be effective in a specific form of ovarian cancer.

"The use of cediranib to help stop cancer cells from repairing damage to their DNA could potentially be useful in a number of cancers that rely on the pathway the drug targets," said the study's lead investigator, Alanna Kaplan. "If we could identify the cancers that depend on this pathway, we may be able to target a number of tumors."

Cediranib inhibits vascular endothelial growth factor (VEGF) receptors that stimulate the formation of blood vessels that support tumor growth. However, it has been less beneficial than the FDA-approved Avastin--an VEGF pathway inhibitor. On the other hand, Olaparib--the first approved DNA repair drug, inhibits a DNA repair enzyme called PARP which eradicates cancer cells with DNA defects in DNA repair from mutations in two DNA repair genes--BRCA1 and BRCA2.

DNA illustration. Credit: © Kirsty Pargeter / Adobe Stock

"There is a lot of interest in the cancer field in developing DNA repair inhibitors because they will greatly help treatments, like radiotherapy and chemotherapy, that aim to destroy DNA in cancer cells," said the senior author of the study, Peter M. Glazer, M.D. "People are recognizing that manipulating DNA repair could be very advantageous to boosting the benefit of traditional cancer treatment."

However, the combination of cediranib and olaparib was effective in ovarian cancers that did not include BRCA1/BRCA2 mutations. This lead to the launch of several clinical trials that tested the drug in duo for different types of cancers, such as prostate and lung cancer.

"The goal now is to investigate how we can broaden the potential of this synthetic lethality to other cancer types," said Glazer.

Source: Yale University News

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
OCT 22, 2020
Neuroscience
Placebos Impact Brain Patterns for Emotional Processing
OCT 22, 2020
Placebos Impact Brain Patterns for Emotional Processing
Researchers from Michigan State University have found that placebos reduce markers of emotional distress- even when the ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 08, 2020
Neuroscience
Psychedelic DMT Improves Memory by Neurogenesis
NOV 08, 2020
Psychedelic DMT Improves Memory by Neurogenesis
Researchers from the Complutense University of Madrid in Spain have found that dimethyltryptamine (DMT), the psychoactiv ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
Loading Comments...